This year, the WHINN – Week of Health and INNovation conference hosts the Round Table “Denmark has a four-year trial for prescribing medical cannabis. How can all parties involved benefit most from this?”. Come and join the debate at WHINN, October 11th in Odense, Denmark. A unique opportunity in a European context, where Industry, Government, Researchers, Doctors and Patient Association meet to discuss the four-year trial for prescribing medical cannabis.
Since late 2017, two of the world’s largest players within medical cannabis, Canopy Growth Corporation and Aurora Cannabis Inc (both from Canada), have started their European operations in Odense. Both companies created Joint Ventures with Danish partners and these months Spectrum Cannabis Denmark (part of Canopy Growth Corporation) and Aurora Nordic Cannabis are building up dedicated production capacities in Odense, with plans of becoming Europe’s largest producer of medical cannabis.
Furthermore, University of Southern Denmark (SDU) is researching the use of medical cannabis. Thus, Odense finds itself in the centre of a rising trend in today’s healthcare.
At WHINN Mark Ware will be one of the participants. Mark Ware is a world-renowned pain specialist and medical cannabis researcher, with around 20 years of research in medical cannabis. and will give the international concrete learnings and give an overview on the international science projects within the field.
“As a physician and researcher, I am aware of the important issues that health professionals will have to consider regarding cannabis use,” says Mark Ware.
Four-year trial for prescribing medical cannabis
Medical cannabis is a highly sensitive subject for many. The debate not only includes patients and medical companies, but also relatives, research institutions, doctors and host of others.
In Denmark, three types of cannabis derivates were approved for medical use by the Danish Medicines Agency in 2011, but they require prescription. Cannabis in other forms such as hashish and the raw plant are illegal. However, from 2018, Denmark has a four-year trial for doctors to prescribe medical cannabis to patients. Consequently, the question of Cannabis’ use is no longer debated as a pro or con, but how can all parties involved benefit most from this 4-year trial?
Potential benefits during the trial period
At this Round Table, participants will share results, knowhow and experiences. Rikke Jakobsen from Cannabis Danmark, an association dedicated to making Denmark a pioneer in the development and use of medical cannabis, and Anna Skat Nielsen from the Danish Ministry of Health, are among two of the leaders heading the discussion, and moderator of the day is Dr. Med. Hans Peder Graversen.
- Time: Thursday 11th of October
- Place: Odense Congress Center
- WHINN: WHINN is a conference on health tech and health innovation.
- See the full program for WHINN here
- Register on www.whinn.dk/registration
Participants at the Round Table:
- Anna Skat Nielsen, Head of Division, The Danish Ministry of Health, Office for Pharmaceutical Policy
- Dr. Marc Ware, Associate Professor McGill Univeristy & CMO Canopy Growth Corporation
- Rime El-Houri, Assistant Professor, Ph. D. Chemical Engineering, SDU
- Janne Kudsk Klitgaard, Associate Professor, Institute of Clinical Research, SDU
- Rikke Jakobsen, Head of Secretary, Cannabis Danmark
- Lasse Skovgaard Director, Research and Documentation at The Danish MS Society
- Nanna Cornelius, Project Manager at Danish Cancer Association
- Moderator Dr. Med. Hans Peder Graversen
+45 5177 7344